Jeffrey Z. Mann
Known title: SVP, GC, Head Corp. Dev., SecyCIK: 0001784562
Jeffrey Z. Mann's purchase track record
Jeffrey Z. Mann has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2026 | EMBC | $100K | pending | pending | — |
| 8/10/2023 | EMBC | $102K | -28.9% | -13.3% | +11.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| EMBC | ▲ Buy | Open Market | 20,000 | $100K | 8/12/2026 | View on chart |
| EMBC | ▲ Buy | Grant | 79,555 | $0 | 11/26/2025 | View on chart |
| EMBC | ▲ Buy | Grant | 24,495 | $0 | 11/26/2025 | View on chart |
| EMBC | ▼ Sell | Tax Withholding | 19,605 | $246K | 11/26/2025 | View on chart |
| EMBC | ▼ Sell | Tax Withholding | 5,285 | $63K | 4/4/2025 | View on chart |
| EMBC | ▼ Sell | Tax Withholding | 8,016 | $150K | 11/26/2024 | View on chart |
| EMBC | ▲ Buy | Grant | 50,803 | $0 | 11/26/2024 | View on chart |
| EMBC | ▲ Buy | Grant | 45,741 | $0 | 11/26/2023 | View on chart |
| EMBC | ▼ Sell | Tax Withholding | 3,715 | $65K | 11/26/2023 | View on chart |
| EMBC | ▲ Buy | Open Market | 4,700 | $102K | 8/10/2023 | View on chart |
| EMBC | ▼ Sell | Tax Withholding | 1,431 | $47K | 11/26/2022 | View on chart |
| EMBC | ▲ Buy | Grant | 19,674 | $0 | 11/26/2022 | View on chart |
| EMBC | ▲ Buy | Grant | 16,281 | $0 | 4/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Concentra Group Hits 52-Week High Amid Medical Services Trends
Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.
Concentra Group Hits 52-Week High Amid Medical Services Trends. Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.